<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        193-334-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TARGOPLANIN 200 mg injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TEICOPLANIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        68.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="HIKMA ITALIA SPA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            HIKMA ITALIA SPA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01XA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Targoplanin is an antibiotic. It contains a medicine called &lsquo;teicoplanin&rsquo;. It works by killing the bacteria that cause infections in your body.</p><p>&nbsp;</p><p>Targoplanin is used in adults and children (including newborn babies) to treat bacterial infections of:</p><ul><li>The skin and underneath the skin - sometimes called &lsquo;soft tissue&rsquo;</li><li>The bones and joints</li><li>The lung</li><li>The urinary tract</li><li>The heart - sometimes called &lsquo;endocarditis&rsquo;</li><li>The abdominal wall - peritonitis</li><li>The blood, when caused by any of the conditions listed above</li></ul><p>&nbsp;</p><p>Targoplanin can be used to treat some infections caused by &lsquo;Clostridium difficile&rsquo; bacteria in the gut. For this, the solution is taken by mouth.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Targoplanin if:</strong></p><ul><li>You are allergic to teicoplanin or any of the other ingredients of this medicine (listed in section 6).</li></ul><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before you are</p><p>given Targoplanin if:</p><ul><li>You are allergic to an antibiotic called &lsquo;vancomycin&rsquo;</li><li>You have had a flushing of your upper part of your body (red man syndrome)</li><li>You have a decrease in platelet count (thrombocytopenia)</li><li>You have kidney problems</li><li>You are taking other medicines which may cause hearing problems and/or kidney problems. You may have regular tests to check if your kidneys and/or liver are working properly (see &lsquo;Other medicines and Targoplanin&rsquo;).</li></ul><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before you are given Targoplanin.</p><p>&nbsp;</p><p>Serious skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP) have been reported with the use of teicoplanin. If you develop a serious rash or other skin symptoms as described in section 4, stop taking Targoplanin and contact your doctor or seek medical attention immediately.</p><p>&nbsp;</p><p><em>Tests:</em></p><p>During treatment you may have tests to check your blood, your kidneys, your liver and/or your hearing. This is more likely if:</p><ul><li>Your treatment will last for a long time</li><li>You need to be treated with high loading doses (12mg/kg twice a day)</li><li>You have a kidney problem</li><li>You are taking or may take other medicines that may affect your nervous system, kidneys or hearing.</li></ul><p>&nbsp;</p><p>In people who are given Targoplanin for a long time, bacteria that are not affected by the antibiotic may grow more than normal - your doctor will check for this.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Targoplanin</strong></p><p>Tell your doctor, pharmacist or nurse if you are using, have recently used or might use any other medicines. This is because Targoplanin can affect the way some other medicines work. Also, some medicines can affect the way Targoplanin works.</p><p>&nbsp;</p><p>In particular, tell your doctor, pharmacist or nurse if you are taking the following medicines:</p><ul><li>Aminoglycosides as they must not be mixed together with Targoplanin in the same injection. They may also cause hearing problems and/or kidney problems.</li><li>Amphotericin B - a medicine that treats fungal infections which may cause hearing problems and/or kidney problems</li><li>Ciclosporin - a medicine that affects the immune system which may cause hearing problems and/or kidney problems</li><li>Cisplatin - a medicine that treats malignant tumors which may cause hearing problems and/or kidney problems</li><li>Water tablets (such as furosemide) - also called &lsquo;diuretics&rsquo; which may cause hearing problems and/or kidney problems.</li></ul><p>&nbsp;</p><p>If any of the above apply to you, (or you are not sure), talk to your doctor, pharmacist or nurse before being given Targoplanin.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant, think that you might be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before being given this medicine. They will decide whether or not you are given this medicine while you are pregnant. There may be a potential risk of inner ear and kidney problems.</p><p>&nbsp;</p><p>Tell your doctor if you are breast-feeding, before being given this medicine. He/she will decide whether or not you can keep breast-feeding, while you are given teicoplanin.</p><p>&nbsp;</p><p>Studies in animal reproduction have not shown evidence of fertility problems.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>You may have headaches or feel dizzy while being treated with Targoplanin. If this happens, do not drive or use any tools or machines.</p><p><strong>&nbsp;</strong></p><p><strong>Targoplanin contains sodium</strong></p><p>Targoplanin contains sodium. Each vial of Targoplanin 200 mg Powder for Solution for Injection/Infusion/Oral Solution<strong> </strong>contains 9.43 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><em>The recommended dose is</em></strong></p><p><strong>Adults and children (12 years and over) with no kidney problems</strong></p><p><em>Skin and soft tissue, lung and urinary tract infections</em></p><ul><li>Starting dose (for the first three doses): 6 mg for every kilogram of body weight, given every 12 hours, by injection into a vein or muscle.</li><li>Maintenance dose: 6 mg for every kilogram of body weight), given once a day, by injection into a vein or muscle.</li></ul><p>&nbsp;</p><p><em>Bone and joint infections, and heart infections</em></p><ul><li>Starting dose (for the first three to five doses): 12 mg for every kilogram of body weight, given every 12 hours, by injection into a vein.</li><li>Maintenance dose: 12 mg for every kilogram of body weight, given once a day, by injection into a vein or muscle.</li></ul><p>&nbsp;</p><p><strong>Infection caused by &lsquo;Clostridium difficile&rsquo; bacteria</strong></p><p>The recommended dose is 100 to 200 mg by mouth, twice a day for 7 to 14 days.</p><p>&nbsp;</p><p><strong>Adults and elderly patients with kidney problems</strong></p><p>If you have kidney problems, your dose will usually need to be lowered after the fourth day of treatment:</p><ul><li>For people with mild and moderate kidney problems - the maintenance dose will be given every two days, or half of the maintenance dose will be given once a day.</li><li>For people with severe kidney problems or on haemodialysis - the maintenance dose will be given every three days, or one-third of the maintenance dose will be given once a day.</li></ul><p>&nbsp;</p><p><em>Peritonitis for patients on peritoneal dialysis</em></p><p>The starting dose is 6 mg for every kilogram of body weight, as a single injection into a vein, followed by:</p><ul><li>Week one: 20 mg/L in each dialysis bag</li><li>Week two: 20 mg/L in every other dialysis bag</li><li>Week three: 20 mg/L in the overnight dialysis bag.</li></ul><p>&nbsp;</p><p><strong>Babies (from birth to the age of 2 months)</strong></p><ul><li>Starting dose (on the first day): 16 mg for every kilogram of body weight, as an infusion through a drip into a vein.</li><li>Maintenance dose: 8 mg for every kilogram of body weight, given once a day, as an infusion through a drip into a vein.</li></ul><p>&nbsp;</p><p><strong>Children (from 2 months to 12 years)</strong></p><ul><li>Starting dose (for the first three doses): 10 mg for every kilogram of body weight, given every 12 hours, by injection into a vein.</li><li>Maintenance dose: 6 to 10 mg for every kilogram of body weight, given once a day, by injection into a vein.</li></ul><p><strong>&nbsp;</strong></p><p><strong>How Targoplanin is given</strong></p><p>The medicine will normally be given to you by a doctor or nurse.</p><ul><li>It will be given by injection into a vein (intravenous use) or muscle (intramuscular use).</li><li>It can also be given as an infusion through a drip into a vein.</li></ul><p>&nbsp;</p><p>Only the infusion should be given in babies from birth to the age of 2 months.</p><p>&nbsp;</p><p>To treat certain infections, the solution may be taken by</p><p>mouth (oral use).</p><p>&nbsp;</p><p><strong>If you have more </strong><strong>Targoplanin</strong><strong> than you should</strong></p><p>It is unlikely that your doctor or nurse will give you too</p><p>much medicine. However, if you think you have been given too much Targoplanin or if you are agitated, talk to your doctor or nurse straight away.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to have </strong><strong>Targoplanin</strong></p><p>Your doctor or nurse will have instructions about when to give you Targoplanin. It is unlikely that they will not give you the medicine as prescribed. However, if you are worried, talk to your doctor or nurse.</p><p>&nbsp;</p><p><strong>If you stop having </strong><strong>Targoplanin</strong></p><p>Do not stop having this medicine without first talking to</p><p>your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects,</p><p>although not everybody gets them.</p><p><strong>&nbsp;</strong></p><p><strong><em>Serious side effects</em></strong></p><p>Stop your treatment and tell your doctor or nurse straight away, if you notice any of the following serious side effects - you may need urgent medical treatment:</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><ul><li>Sudden life-threatening allergic reaction - the signs may include: difficulty in breathing or wheezing, swelling, rash, itching, fever, chills.</li></ul><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1000 people)</strong></p><ul><li>Flushing of the upper body.</li></ul><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><ul><li>Blistering of the skin, mouth, eyes or genitals &ndash; these may be signs of something called &lsquo;toxic epidermal necrolysis&rsquo; or &lsquo;Stevens-Johnson syndrome&rsquo;</li><li>Red scaly widespread rash with bumps under the skin (including your skin folds, chest, abdomen, (including stomach), back and arms) and blisters accompanied by fever - these may be symptoms of something called &lsquo;Acute generalized exanthematous pustulosis (AGEP)&rsquo;or</li><li>&lsquo;Drug reaction with eosinophilia and systemic symptoms (DRESS)&rsquo;. DRESS appears initially as flu-like symptoms and a rash on the face then an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes.</li></ul><p>&nbsp;</p><p>Tell your doctor or nurse straight away, if you notice any of the side effects above.</p><p>&nbsp;</p><p><strong><em>Tell your doctor or nurse straight away, if you notice any of the following serious side effects - you may need urgent medical treatment:</em></strong></p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><ul><li>Swelling and clotting in a vein</li><li>Difficulty in breathing or wheezing (bronchospasm)</li><li>Getting more infections than usual - these could be signs of a decrease in your blood cell count.</li></ul><p><em>&nbsp;</em></p><p><strong>Not known (frequency cannot be estimated from the</strong></p><p><strong>available data)</strong></p><ul><li>Lack of white blood cells - the signs may include: fever, severe chills, sore throat or mouth ulcers (agranulocytosis)</li><li>Kidney problems or changes in the way your kidneys work - shown in tests. Frequency or severity of kidney problems may be increased if you receive higher doses</li><li>Epileptic fits.</li></ul><p>&nbsp;</p><p>Tell your doctor or nurse straight away, if you notice any of the side effects above.</p><p><strong>&nbsp;</strong></p><p><strong><em>Other side effects</em></strong></p><p>Talk to your doctor, pharmacist or nurse if you get any of these:</p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><ul><li>Rash, erythema, pruritus</li><li>Pain</li><li>Fever</li></ul><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><ul><li>Decrease in platelet count</li><li>Raised blood levels of liver enzymes</li><li>Raised in blood levels of creatinine (to monitor your kidney)</li><li>Hearing loss, ringing in the ears or a feeling that you, or things around you are moving.</li><li>Feeling or being sick (vomiting), diarrhea</li><li>Feeling dizzy or headache.</li></ul><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><ul><li>Infection (abscess).</li></ul><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the</strong></p><p><strong>available data)</strong></p><ul><li>Problems where the injection was given - such as reddening of the skin, pain or swelling.</li><li>Low levels of all types of blood cells.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package.</p><p>Chemical and physical in-use stability of the reconstituted and diluted solution prepared as recommended has been demonstrated for 24 hours at 2 to 8&deg;C.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is teicoplanin.</p><p>&nbsp;</p><p>Each vial of Targoplanin 200 mg Powder for Solution for Injection/Infusion/Oral Solution contains 200 mg teicoplanin.</p><p><strong>&nbsp;</strong></p><p>The other ingredients are sodium chloride and sodium hydroxide.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Targoplanin 200 mg Powder for Solution for Injection/Infusion/Oral Solution is white to pale yellow solid having the characteristic appearance of products prepared by freeze drying in 10 ml clear glass vials with grey rubber stoppers and aluminum caps.   

After reconstitution, it is a clear solution free from visible particles. 

The color of the solution may vary from yellowish to dark yellow.

Pack size: 1 Vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturer</strong></p><p>Hikma Italia S.P.A.</p><p>Viale Certosa, 10</p><p>27100 Pavia, Italy</p><p>Tel: + (39-0382) 1751844/+ (39-0382) 1751801</p><p>Fax: + (39-0382) 422745</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 05/2023; version number SA2.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تارجوبلانين هو مضاد حيوي. يحتوي على دواء يسمى &rsquo;تيكوبلانين&lsquo;. يعمل من خلال قتل البكتيريا التي تسبب العدوى في جسمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم تارجوبلانين لدى البالغين والأطفال (بما في ذلك الأطفال حديثي الولادة) لعلاج أنواع العدوى البكتيرية لما يلي:</p><ul dir="rtl"><li>الجلد وتحت الجلد - يطلق عليه أحياناً &rsquo;الأنسجة الرخوة&lsquo;</li><li>العظام والمفاصل</li><li>الرئة</li><li>المسالك البولية</li><li>القلب - يطلق عليها أحياناً &rsquo;التهاب الشغاف&lsquo;</li><li>جدار المعدة - التهاب الصّفاق</li><li>الدم، عندما ينطبق عليك أي من الحالات المذكورة أعلاه</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن استخدام تارجوبلانين لعلاج بعض أنواع العدوى التي تحدث بسبب بكتيريا &quot;المِطثية&nbsp;العَسيرَة&quot; في الأمعاء. لهذا العلاج، يؤخذ المحلول عن طريق الفم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم </strong><strong>تارجوبلانين</strong><strong> </strong><strong>إذا:</strong></p><ul dir="rtl"><li>كنت تعاني من حساسية لتيكوبلانين أو أي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL">تحدث مع طبيبك، الصيدلي أو الممرض قبل أن يتم إعطاؤك تارجوبلانين إذا:</p><ul dir="rtl"><li>كنت تعاني من حساسية لمضاد حيوي يطلق عليه &rsquo;فانكوميسين&lsquo;</li><li>عانيت في السابق من توّرد في الجزء العلوي من جسمك (متلازمة الرجل الأحمر)</li><li>كنت تعاني من انخفاض في عدد الصفائح الدموية (قلّة الصفيحات)</li><li>كنت تعاني من مشاكل في الكلى</li><li>كنت تتناول أدوية أخرى والتي قد تسبب مشاكل في السمع و/أو مشاكل في الكلى. قد تكون لديك فحوصات منتظمة للتحقق مما إذا كانت كليتيك و/أو كبدك يعملان بشكل جيّد (انظر &rsquo;الأدوية أخرى وتارجوبلانين)</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان أي مما يلي ينطبق عليك (أو لم تكن متأكداً)، أخبر طبيبك، الصيدلي أو الممرض قبل أن يتم إعطاؤك تارجوبلانين.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن تفاعلات جلدية شديدة تشمل متلازمة ستيفنز جونسون، تفاعل دوائي مع فرط الحمضات والأعراض الجهازية، بثور طفيلية حادة معممة أثناء استعمال تيكوبلانين. إذا عانيت من طفح خطير أو أي أعراض جلدية أخرى كما هو مبين في القسم 4، توقف عن تناول تارجوبلانين وتواصل مع طبيبك أو اطلب العناية الطارئة على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>الفحوصات:</em></p><p dir="RTL">خلال فترة العلاج، قد تحتاج لإجراء فحوصات لفحص الدم، كليتيك، كبدك و/أو سمعك. هذا أكثر احتمالاً إذا:</p><ul dir="rtl"><li>كان علاجك سيستمر لفترة طويلة</li><li>كنت تحتاج للعلاج بجرعات تحاميل مرتفعة (12 ملغم/كغم مرتين في اليوم)</li><li>كنت تعاني من مشكلة في الكلى</li><li>كنت تتناول أو قد تتناول أدوية أخرى والتي قد تؤثر على الجهاز العصبي، الكليتين أو السمع.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">في الأشخاص الذين يتم إعطاؤهم تارجوبلانين لفترة طويلة، قد تنمو البكتيريا التي لا تتأثر بالمضاد الحيوي أكثر من الطبيعي - سيتحقق طبيبك من ذلك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى و</strong><strong>تارجوبلانين</strong></p><p dir="RTL">أخبر طبيبك، الصيدلي أو الممرض إذا كنت تستخدم، استخدمت مؤخراً أو قد تستخدم أي أدوية أخرى. ذلك لأن تارجوبلانين<strong> </strong>قد يؤثر على طريقة عمل بعض الأدوية الأخرى. أيضاً، بعض الأدوية قد تؤثر على طريقة عمل تارجوبلانين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك، الصيدلي أو الممرض إذا كنت تتناول أيّ من الأدوية التالية على وجه الخصوص:</p><ul dir="rtl"><li>الجليكوزيدات الأمينية، حيث لا يجب مزجها مع تارجوبلانين في نفس الحقنة. قد تسبب أيضاً مشاكل في السمع و/أو مشاكل في الكلى.</li><li>أمفوتريسين ب - هو دواء يعالج العدوى الفطرية والذي قد يسبب مشاكل في السمع و/أو مشاكل في الكلى.</li><li>سيكلوسبورين - هو دواء يؤثر على جهاز المناعة والذي قد يسبب مشاكل في السمع و/أو مشاكل في الكلى.</li><li>سيسبلاتين - هو دواء يعالج الأورام الخبيثة والذي قد يسبب مشاكل في السمع و/أو مشاكل في الكلى.</li><li>أقراص الماء (مثل فوروسيميد) - يطلق عليها أيضاً &rsquo;مدرات البول&lsquo; والتي قد تسبب مشاكل في السمع و/أو مشاكل في الكلى.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان ينطبق عليك أي مما سبق، (أو لم تكن متأكداً)، تحدث مع طبيبك، الصيدلي أو الممرض قبل أن يتم إعطاؤك تارجوبلانين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل، الرضاعة والخصوبة</strong></p><p dir="RTL">يرجى استشارة طبيبك، الصيدلي أو الممرض إذا كنتِ حاملاً، تعتقدين بأنك حامل أو تخططين لذلك قبل أن يتم إعطاؤك هذا الدواء. سيتم تحديد ما إذا كان يجب إعطاؤك هذا الدواء أثناء فترة الحمل. قد يكون هناك خطر محتمل لمشاكل الأذن الداخلية والكلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبري طبيبك إذا كنتِ تقومين بالرضاعة الطبيعية، قبل أن يتم إعطاؤك هذا الدواء. سيحدد ما إذا كان يمكنك الاستمرار في الرضاعة الطبيعية، أثناء إعطائك تيكوبلانين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لم تُظهر الدراسات التي أجريت حول التكاثر الحيواني دليلاً على وجود مشاكل في الخصوبة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">قد تصاب بنوبات صداع أو تشعر بالدوخة أثناء علاجك باستخدام تارجوبلانين. إذا حدث ذلك، تجنب القيادة أو استخدام أي أدوات أو آلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي </strong><strong>تارجوبلانين</strong><strong> </strong><strong>على الصوديوم</strong></p><p dir="RTL">يحتوي تارجوبلانين على الصوديوم. تحتوي كل زجاجة من تارجوبلانين 200 ملغم مسحوق للحل للحقن/للتسريب/لتشكيل المحلول الفموي على 9,43 ملغم صوديوم. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل زجاجة، وبذلك يعتبر &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><em>الجرعة الموصى بها هي </em></strong></p><p dir="RTL"><strong>للبالغين والأطفال (بعمر 12 عاماً فأكثر) دون وجود مشاكل في الكلى </strong></p><p dir="RTL"><em>عدوى الجلد والأنسجة الرخوة، الرئة والمسالك البولية</em></p><ul dir="rtl"><li>الجرعة الابتدائية (للجرعات الثلاث الأولى): 6 ملغم لكل كيلوغرام من وزن الجسم، يتم إعطاؤها كل 12 ساعة، عن طريق الحقن في الوريد أو في العضل.</li><li>جرعة المداومة: 6 ملغم لكل كيلوغرام من وزن الجسم، يتم إعطاؤها مرة واحدة يومياً، عن طريق الحقن في الوريد أو في العضل.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><em>عدوى العظام والمفاصل، وعدوى القلب</em></p><ul dir="rtl"><li>الجرعة الابتدائية (لأول ثلاث إلى خمس جرعات): 12 ملغم لكل كيلوغرام من وزن الجسم، يتم إعطاؤها كل 12 ساعة، عن طريق الحقن في الوريد.</li><li>جرعة المداومة: 12 ملغم لكل كيلوغرام من وزن الجسم، يتم إعطاؤها مرة واحدة يومياً، عن طريق الحقن في الوريد أو في العضل.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العدوى اتي تسببها بكتيريا<em> </em>&rsquo;المطثية العسيرة</strong>&lsquo;</p><p dir="RTL">الجرعة الموصى بها هي 100 ملغم إلى 200 ملغم عن طريق الفم، مرتان يومياً لمدة تتراوح ما بين 7 إلى 14 يوماً.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>المرضى البالغون وكبار السن الذين يعانون من مشاكل في الكلى</strong></p><p dir="RTL">إذا كنت تعاني من مشاكل في الكلى، فعادة ستحتاج إلى تخفيض الجرعة بعد اليوم الرابع من العلاج:</p><ul dir="rtl"><li>للأشخاص الذين يعانون من مشاكل خفيفة أو متوسطة في الكلى - سيتم إعطاؤهم جرعة المداومة كل يومين، أو نصف جرعة المداومة مرة واحدة في اليوم.</li><li>للأشخاص الذين يعانون من مشاكل شديدة في الكلى أو يخضعون لغسيل الكلى - سيتم إعطاؤهم جرعة المداومة كل ثلاثة أيام، أو ثلث جرعة المداومة مرة واحدة في اليوم.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><em>التهاب الصّفاق للمرضى الذين </em><em>يخضعون لغسيل</em><em> </em><em>صفاقي</em></p><p dir="RTL">الجرعة الابتدائية هي 6 ملغم لكل كيلوغرام من وزن الجسم، كحقنة لمرة واحدة في الوريد، يتبعها ما يلي:</p><ul dir="rtl"><li>الأسبوع الأول: 20 ملغم/لتر في كل كيس من أكياس الغسيل الكلوي</li><li>الأسبوع الثاني: 20 ملغم/لتر في كيس من كل كيسين من أكياس الغسيل الكلوي</li><li>الأسبوع الثالث: 20 ملغم/لتر على مدار الليل في كيس الغسيل الكلوي.</li></ul><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال (من الولادة إلى عمر شهرين)</strong></p><ul dir="rtl"><li>الجرعة الإبتدائية (في اليوم الأول): 16 ملغم لكل كيلوغرام من وزن الجسم، يتم إعطاؤها عن طريق التسريب من خلال التقطير في الوريد.</li><li>جرعة المداومة: 8 ملغم لكل كيلوغرام من وزن الجسم، يتم إعطاؤها مرة يومياً، عن طريق التسريب من خلال التقطير في الوريد.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال (من عمر شهرين إلى 12 عاماً)</strong></p><ul dir="rtl"><li>الجرعة الإبتدائية (للجرعات الثلاث الأولى): 10 ملغم لكل كيلوغرام من وزن الجسم، يتم إعطاؤها كل 12 ساعة، عن طريق الحقن في الوريد.</li><li>جرعة المداومة: 6 إلى 10 ملغم لكل كيلوغرام من وزن الجسم، يتم إعطاؤها مرة واحدة يومياً، عن طريق الحقن في الوريد.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة إعطاء </strong><strong>تارجوبلانين</strong></p><p dir="RTL">عادة ما سيقوم الطبيب أو الممرض بإعطائك الدواء.</p><ul dir="rtl"><li>سيتم إعطاؤه عن طريق الحقن في الوريد (الاستخدام الوريدي) أو عن طريق الحقن في العضل (الاستخدام العضلي).</li><li>يمكن إعطاؤه أيضاً عن طريق التسريب من خلال التقطير في الوريد.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">يتم إعطاء الدواء فقط من خلال التسريب للأطفال من عمر الولادة إلى عمر شهرين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لعلاج أنواع معينة من العدوى، يمكن أخذ المحلول عن طريق الفم (استخدام فموي).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا استخدمت </strong><strong>تارجوبلانين</strong><strong> </strong><strong>أكثر من اللازم</strong></p><p dir="RTL">من غير المحتمل أن يقوم طبيبك أو الممرض بإعطائك جرعة زائدة من الدواء. على الرغم من ذلك، إذا كنت تعتقد أنه قد تم إعطاؤك جرعة زائدة من تارجوبلانين أو لديك شعور بالهياج، فتحدث مع طبيبك أو الممرض على الفور.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيت استخدام </strong><strong>تارجوبلانين</strong></p><p dir="RTL">سيكون لدى طبيبك أو الممرض تعليمات حول مواعيد إعطائك تارجوبلانين. من غير المحتمل أن يتم إعطاؤك الدواء بطريقة مخالفة لما تم وصفه لك. على الرغم من ذلك، تحدث مع طبيبك أو الممرض، إذا كنت قلقاً.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا توقفت عن استخدام </strong><strong>تارجوبلانين</strong></p><p dir="RTL">لا تتوقف عن استخدام هذا الدواء دون التحدث إلى طبيبك، الصيدلي أو الممرض أولاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء، يرجى استشارة طبيبك، الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><em>الآثار الجانبية الخطيرة </em></strong></p><p dir="RTL">توقف عن العلاج وأخبر طبيبك أو الممرض على الفور، إذا لاحظت أيّاً من الآثار الجانبية الخطيرة التالية - قد تحتاج إلى علاج طبي عاجل:</p><p dir="RTL"><strong>غير شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص) </strong></p><ul dir="rtl"><li>رد فعل تحسسي مفاجئ مهدد للحياة - قد تشمل العلامات: صعوبة في التنفس أو صفير، تورم، طفح جلدي، حكة، حمّى، قشعريرة.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة (قد تؤثر على ما يصل إلى شخص واحد من كل 1000 شخص)</strong></p><ul dir="rtl"><li>تورّد الجزء العلوي من الجسم.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة (لا يمكن تقدير تكرارها من البيانات المتاحة)</strong></p><ul dir="rtl"><li>تقرحات في الجلد، الفم، العينين أو الأعضاء التناسلية - قد تكون هذه علامات لما يسمى &rsquo;تقشر الأنسجة المتموتة البشروية التسممي&lsquo; أو &rsquo;متلازمة ستيفنز جونسون&lsquo;</li><li>طفح جلدي أحمر أو متقشر مع كدمات تحت الجلد ( تشمل ثنيات الجلد، الصدر، البطن، (بما في ذلك المعدة) الظهر و الأذرع) و البثرات المصاحبة للحمى- قد تكون هذه أعراض لما &quot;يسمى البثور الطفحى الحاد المعمم&quot; أو</li><li>&rsquo;التفاعل الدوائي مع فرط اليوزينيات والأعراض الجهازية&lsquo;. يظهر في البداية &rsquo;التفاعل الدوائي مع فرط اليوزينيات والأعراض الجهازية&lsquo; كأعراض تشبه أعراض الانفلونزا وطفح على الوجه ثم طفح جلدي منتشر مع ارتفاع في درجة الحرارة، وزيادة مستويات إنزيمات الكبد في فحوصات الدم وزيادة في نوع من خلايا الدم البيضاء (كثرة اليوزينيات) وتضخم الغدد الليمفاوية.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الممرض على الفور، إذا لاحظت أي من الآثار الجانبية أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>أخبر طبيبك أو الممرض على الفور، إذا لاحظت أيّاً من الآثار الجانبية الخطيرة التالية - قد تحتاج إلى علاج طبي عاجل:</em></strong></p><p dir="RTL"><strong>غير شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص) </strong></p><ul dir="rtl"><li>تورم وتجلط في الوريد</li><li>صعوبة في التنفس أو إصدار صفير (تشنجات في القصبة الهوائية)</li><li>الإصابة بالمزيد من العدوى أكثر من المعتاد &ndash; قد تكون هذا علامات انخفاض في عدد خلايا الدم.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة (لا يمكن تقدير تكرارها من البيانات المتاحة)</strong></p><ul dir="rtl"><li>نقص عدد الخلايا الدم البيضاء - قد تشمل العلامات: الحمّى، القشعريرة الشديدة، التهاب الحلق أو تقرحات بالفم (ندرة المُحَبَّبات)</li><li>مشاكل في الكلى أو تغيرات في طريقة عمل كليتيك - كما تبيّن الفحوصات، قد يزداد تكرار أو شدة حدوث مشاكل الكلى عند تناولك جرعات أكبر.</li><li>نوبات صرع.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الممرض على الفور، إذا لاحظت أي من الآثار الجانبية أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>الآثار الجانبية الأخرى</em></strong></p><p dir="RTL">تحدث إلى طبيبك، الصيدلي أو الممرض إذا عانيت من أي ممّا يلي:</p><p dir="RTL"><strong>شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص)</strong></p><ul dir="rtl"><li>طفح جلدي، حمامى، حكة</li><li>ألم</li><li>حمّى</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص)</strong></p><ul dir="rtl"><li>انخفاض في عدد الصفائح الدموية</li><li>ارتفاع في مستويات إنزيمات الكبد في الدم</li><li>زيادة مستوى الكرياتينين في الدم (لمراقبة وظائف الكلى)</li><li>فقدان السمع، طنين في الأذنين أو الشعور بأنك أو بأن الأشياء من حولك تتحرك</li><li>الغثيان أو القيء، الاسهال</li><li>الشعور بدوخة أو بصداع.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة (قد تؤثر على ما يصل إلى شخص واحد من كل </strong><strong>1000</strong><strong> شخص) </strong></p><ul dir="rtl"><li>عدوى (خراجات).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة (لا يمكن تقدير تكرارها من البيانات المتاحة)</strong></p><ul dir="rtl"><li>حدوث مشاكل حول موضع إعطاء الحقنة - مثل احمرار الجلد، الألم أو التورم.</li><li>انخفاض مستويات خلايا الدم بكافة أنواعها.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية.</p><p dir="RTL">تم إثبات الاستقرار الكيميائي والفيزيائي للمحلول المحضر والمخفف على النحو الموصى به لمدة 24 ساعة عند درجة حرارة 2 إلى 8&deg; مئوية.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية &ldquo;EXP&rdquo;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعّالة هي تيكوبلانين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل زجاجة من تارجوبلانين 200 ملغم مسحوق للحل للحقن/للتسريب/لتشكيل المحلول الفموي على 200 ملغم تيكوبلانين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي كلوريد الصوديوم وهيدروكسيد الصوديوم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تارجوبلانين 200 ملغم مسحوق للحل للحقن/للتسريب/لتشكيل المحلول الفموي هي كتلة بيضاء مائلة إلى الأصفر الباهت لها خواص مظهر المستحضرات المحضرة عن طريق التجفيف بالتبريد في زجاجات شفافة بحجم 10 مللتر مع سدادات مطاطية رمادية اللون وأغطية من الألمينيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد الحلّ، هو محلول صافٍ خالٍ من الجزيئات المرئية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتراوح لون المحلول من الأصفر إلى الأصفر الغامق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حجم العبوة: زجاجة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com<br />&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">شركة الحكمة إيطاليا المساهمة العامة المحدودة<br />طريق سيرتوزا، 10<br />27100 بافيا، إيطاليا<br />هاتف: 1751844 (0382-39) +/ 1751801 (0382-39) +<br />فاكس: 422745 (0382-39) +</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه(. من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 05/2023؛ رقم النسخة SA2.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Targoplanin 200 mg Powder for Solution for Injection/Infusion/Oral Solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial of Targoplanin 200 mg Powder for Solution for Injection/Infusion/Oral Solution contains 200 mg teicoplanin.

Excipient with known effect: Sodium.
Each vial of Targoplanin 200 mg Powder for Solution for Injection/Infusion/Oral Solution contains 9.43 mg sodium.  

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for injection/infusion/Oral Solution.

White to pale yellow solid powder having the characteristic appearance of products prepared by freeze drying.

After reconstitution, clear solution free from visible particles.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Targoplanin is indicated in adults and in children from birth for the parenteral treatment of the following infections (see sections 4.2, 4.4 and 5.1):</p><ul><li>Complicated skin and soft tissue infections,</li><li>Bone and joint infections,</li><li>Hospital acquired pneumonia,</li><li>Community acquired pneumonia,</li><li>Complicated urinary tract infections,</li><li>Infective endocarditis,</li><li>Peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD),</li><li>Bacteraemia that occurs in association with any of the indications listed above.</li></ul><p>&nbsp;</p><p>Targoplanin is also indicated as an alternative oral treatment for&nbsp;Clostridium difficile&nbsp;infection-associated diarrhoea and colitis.</p><p>&nbsp;</p><p>Where appropriate, targoplanin should be administered in combination with other antibacterial agents.</p><p>&nbsp;</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Posology</em></strong></p><p>The dose and duration of treatment should be adjusted according to the underlying type and severity of infection and clinical response of the patient, and patient factors such as age and renal function.</p><p>&nbsp;</p><p><strong>Measurement of serum concentrations</strong></p><p>Teicoplanin trough serum concentrations should be monitored at steady state after completion of the loading dose regimen in order to ensure that a minimum trough serum concentration has been reached:</p><ul><li>For most Gram-positive infections, teicoplanin trough levels of at least 10 mg/L when measured by High Performance Liquid Chromatography (HPLC), or at least 15 mg/L when measured by Fluorescence Polarization Immunoassay (FPIA) method.</li><li>For endocarditis and other severe infections, teicoplanin trough levels of 15-30 mg/L when measured by HPLC, or 30-40 mg/L when measured by FPIA method.</li></ul><p>&nbsp;</p><p>During maintenance treatment, teicoplanin trough serum concentrations monitoring may be performed at least once a week to ensure that these concentrations are stable.</p><p>&nbsp;</p><p><strong>Adults and elderly patients with normal renal function</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong><em>Indications</em></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Loading dose</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Maintenance dose</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Loading dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Targeted trough concentrations at day 3 to 5</strong></p></td><td style="vertical-align:top"><p><strong>Maintenance dose</strong></p></td><td style="vertical-align:top"><p><strong>Targeted trough concentrations during maintenance</strong></p></td></tr><tr><td style="vertical-align:top"><p>-Complicated skin and soft tissue infections</p><p>- Pneumonia</p><p>-Complicated urinary tract infections</p></td><td style="vertical-align:top"><p>6 mg/kg body weight every 12 hours for 3 intravenous or intramuscular administrations</p></td><td style="vertical-align:top"><p>&gt;15 mg/L<sup>1</sup></p></td><td style="vertical-align:top"><p>6 mg/kg body weight intravenous or intramuscular once a day</p></td><td style="vertical-align:top"><p>&gt;15 mg/L<sup>1</sup>&nbsp;once a week</p></td></tr><tr><td style="vertical-align:top"><p>-Bone and joint infections</p></td><td style="vertical-align:top"><p>12 mg/kg body weight every 12 hours for 3 to 5 intravenous administrations</p></td><td style="vertical-align:top"><p>&gt;20 mg/L<sup>1</sup></p></td><td style="vertical-align:top"><p>12 mg/kg body weight intravenous or intramuscular once a day</p></td><td style="vertical-align:top"><p>&gt;20 mg/L<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>-Infective endocarditis</p></td><td style="vertical-align:top"><p>12 mg/kg body weight every 12 hours for 3 to 5 intravenous administrations</p></td><td style="vertical-align:top"><p>30-40 mg/L<sup>1</sup></p></td><td style="vertical-align:top"><p>12 mg/kg body weight intravenous or intramuscular once a day</p></td><td style="vertical-align:top"><p>&gt;30 mg/L<sup>1</sup></p></td></tr></tbody></table><p><sup>1&nbsp;</sup>Measured by FPIA</p><p>&nbsp;</p><p>The dose is to be adjusted on bodyweight whatever the weight of the patient.</p><p>&nbsp;</p><p><strong>Duration of treatment</strong></p><p>The duration of treatment should be decided based on the clinical response. For infective endocarditis a minimum of 21 days is usually considered appropriate. Treatment should not exceed 4 months.</p><p>&nbsp;</p><p><strong>Combination therapy</strong></p><p>Teicoplanin has a limited spectrum of antibacterial activity (Gram positive). It is not suitable for use as a single agent for the treatment of some types of infections unless the pathogen is already documented and known to be susceptible or there is a high suspicion that the most likely pathogen(s) would be suitable for treatment with teicoplanin.</p><p>&nbsp;</p><p><strong>Clostridium difficile infection-associated diarrhoea and colitis</strong></p><p>The recommended dose is 100-200 mg administered orally twice a day for 7 to 14 days.</p><p>&nbsp;</p><p><strong>Elderly population</strong></p><p>No dose adjustment is required, unless there is renal impairment (see below).</p><p>&nbsp;</p><p><strong>Adults and elderly patients with impaired renal function</strong></p><p>Dose adjustment is not required until the fourth day of treatment, at which time dosing should be adjusted to maintain a serum trough concentration of at least 10 mg/L when measured by HPLC, or at least 15 mg/L when measured by FPIA method.</p><p>&nbsp;</p><p>After the fourth day of treatment:</p><ul><li>In mild and moderate renal insufficiency (creatinine clearance 30-80 ml/min): maintenance dose should be halved, either by administering the dose every two days or by administering half of this dose once a day.</li><li>In severe renal insufficiency (creatinine clearance less than 30 ml/min) and in haemodialysed patients: dose should be one-third the usual dose, either by administering the initial unit dose every third day or by administering one-third of this dose once a day.</li></ul><p>&nbsp;</p><p>Teicoplanin is not removed by haemodialysis.</p><p>&nbsp;</p><p><strong>Patients in continuous ambulatory peritoneal dialysis (CAPD)</strong></p><p>After a single intravenous loading dose of 6 mg/kg bodyweight, 20 mg/L is administered in the bag of the dialysis solution in the first week, 20 mg/L in different bags the second week and then 20 mg/L in the overnight bag in the third week.</p><p>&nbsp;</p><p><strong>Paediatric population</strong></p><p>The dose recommendations are the same in adults and children above 12 years of age.</p><p>&nbsp;</p><p><u>Neonates and infants up to the age of 2 months</u>:</p><p><em>Loading dose</em></p><p>One single dose of 16 mg/kg body weight, administered intravenously by infusion on the first day.</p><p>&nbsp;</p><p><em>Maintenance dose</em></p><p>One single dose of 8 mg/kg body weight administered intravenously by infusion once a day.</p><p>&nbsp;</p><p><u>Children (2 months to 12 years):</u></p><p><em>Loading dose</em></p><p>One single dose of 10 mg/kg body weight administered intravenously every 12 hours, repeated 3 times.</p><p>&nbsp;</p><p><em>Maintenance dose</em></p><p>One single dose of 6-10 mg/kg body weight administered intravenously once a day.</p><p>&nbsp;</p><p><strong><em>Method of administration</em></strong></p><p>Targoplanin should be administered by the intravenous or intramuscular route. The intravenous injection may be administered either as a bolus over 3 to 5 minutes or as a 30-minute infusion.</p><p>&nbsp;</p><p>Only the infusion method should be used in neonates.</p><p>&nbsp;</p><p>For&nbsp;Clostridium difficile&nbsp;infection-associated diarrhoea and colitis, the oral route is to be used.</p><p>&nbsp;</p><p>For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to teicoplanin or to any of the excipients listed in section 6.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Targoplanin should not be administered by intraventricular use.</p><p>&nbsp;</p><p><strong>Hypersensitivity reactions</strong></p><p>Serious, life-threatening hypersensitivity reactions, sometimes fatal, have been reported with teicoplanin (e.g. anaphylactic shock). If an allergic reaction to teicoplanin occurs, treatment should be discontinued immediately and appropriate emergency measures should be initiated.</p><p>&nbsp;</p><p>Teicoplanin must be administered with caution in patients with known hypersensitivity to vancomycin, as crossed hypersensitivity reactions, including fatal anaphylactic shock, may occur.</p><p>&nbsp;</p><p>However, a prior history of &quot;red man syndrome&quot; with vancomycin is not a contraindication to the use of teicoplanin.</p><p>&nbsp;</p><p><strong>Infusion related reactions</strong></p><p>In rare cases (even at the first dose), red man syndrome (a complex of symptoms including pruritus, urticaria, erythema, angioneurotic oedema, tachycardia, hypotension, dyspnoea) has been observed.</p><p>&nbsp;</p><p>Stopping or slowing the infusion may result in cessation of these reactions. Infusion related reactions can be limited if the daily dose is not given via bolus injection but infused over a 30-minute period.</p><p>&nbsp;</p><p><strong>Severe cutaneous adverse reactions</strong></p><p>Severe cutaneous adverse reactions (SCAR) including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), which can be life-threatening or fatal have been reported with the use of teicoplanin (see section 4.8). Acute generalized exanthematous pustulosis (AGEP) has also been reported with the use of teicoplanin (see section 4.8). At the time of prescription, patients should be advised of the signs and symptoms of severe skin reactions (e.g. progressive skin rash often with blisters or mucosal lesions or pustular rash, or any other sign of skin hypersensitivity) and be closely monitored. If signs and symptoms suggestive of severe skin reactions appear, teicoplanin should be withdrawn and alternative treatment should be considered.</p><p>&nbsp;</p><p><strong>Spectrum of antibacterial activity</strong></p><p>Teicoplanin has a limited spectrum of antibacterial activity (<em>Gram-positive</em>). It is not suitable for use as a single agent for the treatment of some types of infections unless the pathogen is already documented and known to be susceptible or there is a high suspicion that the most likely pathogen(s) would be suitable for treatment with teicoplanin.</p><p>&nbsp;</p><p>The rational use of teicoplanin should take into account the bacterial spectrum of activity, the safety profile and the suitability of standard antibacterial therapy to treat the individual patient. On this basis it is expected that in most instances teicoplanin will be used to treat severe infections in patients for whom standard antibacterial activity is considered to be unsuitable.</p><p>&nbsp;</p><p><strong>Thrombocytopenia</strong></p><p>Thrombocytopenia has been reported with teicoplanin (see section 4.8). Periodic haematological examinations, including complete blood count, are recommended during treatment.</p><p>&nbsp;</p><p><strong>Nephrotoxicity</strong></p><p>Nephrotoxicity and renal failure have been reported in patients treated with teicoplanin (see section 4.8). Patients with renal insufficiency, in those receiving the high loading dose regimen of teicoplanin, and those receiving teicoplanin in conjunction with or sequentially with other medicinal products with known nephrotoxic potential (e.g. aminoglycosides, colistin, amphotericin B, ciclosporin, and cisplatin) should be carefully monitored, and should get auditory tests (see &ldquo;Ototoxicity&rdquo; below).</p><p>&nbsp;</p><p>Since teicoplanin is mainly excreted by the kidney, the dose of teicoplanin must be adapted in patients with renal impairment (see section 4.2).</p><p>&nbsp;</p><p><strong>Ototoxicity</strong></p><p>As with other glycopeptides, ototoxicity (deafness and tinnitus) has been reported in patients treated with teicoplanin (see section 4.8). Patients who develop signs and symptoms of impaired hearing or disorders of the inner ear during treatment with teicoplanin should be carefully evaluated and monitored, especially in case of prolonged treatment and in patients with renal insufficiency. Patients receiving teicoplanin in conjunction with or sequentially with other medicinal products with known nephrotoxic and/or neurotoxic/ototoxic potential (e.g. aminoglycosides, colistin, amphotericin B, ciclosporin, cisplatin, furosemide and ethacrynic acid) &nbsp;should be carefully monitored and the benefit of teicoplanin evaluated if hearing deteriorates.</p><p>&nbsp;</p><p>Special precautions must be taken when administering teicoplanin in patients who require concomitant treatment with ototoxic and/or nephrotoxic medicinal products for which it is recommended that regular haematology, liver and kidney function tests are carried out.</p><p><strong>&nbsp;</strong></p><p><strong>Superinfection</strong></p><p>As with other antibiotics, the use of teicoplanin, especially if prolonged, may result in overgrowth of non-susceptible organisms. If superinfection occurs during therapy, appropriate measures should be taken.</p><p>&nbsp;</p><p><strong>Targoplanin contains sodium.</strong></p><p>Targoplanin contains sodium. Each vial of Targoplanin 200 mg Powder for Solution for Injection/Infusion/Oral Solution contains 9.43 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific interaction studies have been performed.</p><p>&nbsp;</p><p>Teicoplanin and aminoglycoside solutions are incompatible and must not be mixed for injection; however, they are compatible in dialysis fluid and may be freely used in the treatment of CAPD-related peritonitis. Teicoplanin should be used with care in conjunction with or sequentially with other medicinal products with known nephrotoxic and/or neurotoxic/ototoxic potential. These include e.g. aminoglycosides, colistin, amphotericin B, ciclosporin, cisplatin, furosemide, and ethacrynic acid (see section 4.4 &ldquo;Nephrotoxicity&rdquo; and &ldquo;Ototoxicity&rdquo;). However, there is no evidence of synergistic toxicity in combinations with teicoplanin.</p><p>&nbsp;</p><p>In clinical studies, teicoplanin has been administered to many patients already receiving various medications including other antibiotics, antihypertensives, anaesthetic agents, cardiac medicinal products and antidiabetic agents without evidence of adverse interaction.</p><p>&nbsp;</p><p><strong>Paediatric population</strong></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>There are a limited amount of data from the use of teicoplanin in pregnant women. Studies in animals have shown reproductive toxicity at high doses (see section 5.3): in rats there was an increased incidence of stillbirths and neonatal mortality. The potential risk for humans is unknown.</p><p>&nbsp;</p><p>Therefore, teicoplanin should not be used during pregnancy unless clearly necessary. A potential risk of inner ear and renal damage to the foetus&nbsp;cannot be excluded (see section 4.4).</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p>It is unknown whether teicoplanin is excreted in human milk. There is no information on the excretion of teicoplanin in animal milk. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with teicoplanin should be made taking into account the benefit of breast-feeding to the child and the benefit of teicoplanin therapy to the mother.</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p>Animal reproduction studies have not shown evidence of impairment of fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Targoplanin has minor influence on the ability to drive and use machines. Teicoplanin can cause dizziness and headache. The ability to drive or use machines may be affected. Patients experiencing these undesirable effects should not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Tabulated list of adverse reactions</strong></p><p>In the table below all the adverse reactions, which occurred at an incidence greater than placebo and more than one patient are listed using the following convention:</p><p>Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(&ge;1/100 to &lt;1/10 )</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(&ge;1/1,000 to &lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&ge;1/10,000 to &lt;1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p><p><strong>(&lt;1/10,000)</strong></p></td><td style="vertical-align:top"><p><strong>Not known (cannot be estimated from available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Abscess</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Superinfection (overgrowth of non-susceptible organisms)</p></td></tr><tr><td style="vertical-align:top"><p>Blood and the lymphatic system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Leucopenia, thrombocytopenia, eosinophilia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Agranulocytosis, neutropenia,</p><p>pancytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anaphylactic reaction (anaphylaxis) (see section 4.4)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Drug reaction with eosinophilia and systemic symptoms (DRESS), anaphylactic shock (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Dizziness, headache</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Seizures</p></td></tr><tr><td style="vertical-align:top"><p>Ear and Labyrinth disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Deafness, hearing loss (see section 4.4), tinnitus, vestibular disorder</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Phlebitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Thrombophlebitis</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Bronchospasm</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gastro-intestinal disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Diarrhoea, vomiting, nausea</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash, erythema, pruritus</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Red man syndrome (e.g. Flushing of the upper part of the body) (see section 4.4).</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Toxic epidermal necrolysis, Stevens-Johnson syndrome, Acute generalized exanthematous pustulosis, erythema multiforme, angioedema, dermatitis exfoliative, urticaria (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Renal and Urinary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Renal failure (including renal failure acute) (see below description of selected adverse reactions)*</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Pain, pyrexia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Injection site abscess, chills (rigors)</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Transaminases increased (transient abnormality of transaminases), blood alkaline phosphatase increased (transient abnormality of alkaline phosphatase)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>Description of selected adverse reactions</p><p>*Based on literature reports, the estimated rate of nephrotoxicity in patients receiving low loading dose regimen of average 6 mg/kg twice a day, followed by a maintenance dose of average 6 mg/kg once daily, is around 2%.</p><p>In an observational post-authorisation safety study which enrolled 300 patients with a mean age of 63 years (treated for bone and joint infection, endocarditis or other severe infections) who received the high loading dose regimen of 12 mg/kg twice a day (receiving 5 loading doses as a median) followed by a maintenance dose of 12 mg/kg once daily, the observed rate of confirmed nephrotoxicity was 11.0% (95% CI = [7.4%; 15.5%]) over the first 10 days. The cumulative rate of nephrotoxicity from the start of treatment up to 60 days after the last dose was 20.6% (95% CI = [16.0%; 25.8%]). In patients receiving more than 5 high loading doses of 12 mg/kg twice a day, followed by a maintenance dose of 12 mg/kg once daily, the observed cumulative rate of nephrotoxicity from the start of treatment up to 60 days after the last administration was 27% (95% CI = [20.7%; 35.3%]) (see section 4.4).</p><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms</strong></p><p>Cases of accidental administration of excessive doses to paediatric patients have been reported. In one case agitation occurred in a 29-day-old newborn who had been administered 400 mg intravenously (95 mg/kg).</p><p>&nbsp;</p><p><strong>Management</strong></p><p>Treatment of teicoplanin overdose should be symptomatic.</p><p>&nbsp;</p><p>Teicoplanin is not removed by haemodialysis and only slowly by peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Glycopeptide Antibacterials, ATC code: J01XA 02</p><p>&nbsp;</p><p><strong>Mechanism of action</strong></p><p>Teicoplanin inhibits the growth of susceptible organisms by interfering with cell-wall biosynthesis at a site different from that affected by beta-lactams. Peptidoglycan synthesis is blocked by specific binding to D-alanyl-D-alanine residues.</p><p>&nbsp;</p><p><strong>Mechanism of resistance</strong></p><p>Resistance to teicoplanin can be based on the following mechanisms:</p><ul><li>Modified target structure: this form of resistance has occurred particularly in&nbsp;<em>Enterococcus &nbsp;faecium</em>. The modification is based on exchange of the terminal D-alanine-D-alanine function of the amino-acid chain in a murein precursor with D-Ala-D-lactate, thus reducing the affinity to vancomycin. The responsible enzymes are a newly synthesised D-lactate dehydrogenase or ligase.</li><li>The reduced sensitivity or resistance of staphylococci to teicoplanin is based on the overproduction of murein precursors to which teicoplanin is bound.</li></ul><p>&nbsp;</p><p>Cross-resistance between teicoplanin and the glycoprotein vancomycin may occur. A number of vancomycin-resistant enterococci are sensitive to teicoplanin (Van-B phenotype).</p><p>&nbsp;</p><p><strong>Susceptibility testing breakpoints</strong></p><p>The MICs breakpoints according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST), version 10.0, January 1st, 2020 are displayed in the following table:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Microorganism</strong></p></td><td style="vertical-align:top"><p><strong>Susceptible</strong></p></td><td style="vertical-align:top"><p><strong>Resistant</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus&nbsp;<sup>a, b</sup></em></p></td><td style="vertical-align:top"><p>&le;2 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Coagulase-negative staphylococci&nbsp;<em><sup>a</sup></em></p></td><td style="vertical-align:top"><p>&le;4 mg/L</p></td><td style="vertical-align:top"><p>&gt;4 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Enterococcus</em>&nbsp;spp.</p></td><td style="vertical-align:top"><p>&le;2 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Streptococcus groupsA, B, C, G&nbsp;<em><sup>b</sup></em></p></td><td style="vertical-align:top"><p>&le;2 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae</em>&nbsp;<em><sup>b</sup></em></p></td><td style="vertical-align:top"><p>&le;2 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Viridans group streptococci<em>&nbsp;<sup>b</sup></em></p></td><td style="vertical-align:top"><p>&le;2 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>a&nbsp;</em>Glycopeptide MICs are method dependent and should be determined by broth microdilution (reference ISO 20776-1).&nbsp;<em>S. aureus</em>&nbsp;with vancomycin MIC values of 2 mg/L are on the border of the wild type MIC distribution and there may be an impaired clinical response.</p><p><em>b&nbsp;</em>Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Pharmacokinetic/Pharmacodynamic relationship</strong></p><p>Teicoplanin antimicrobial activity depends essentially on the duration of time during which the substance level is higher than the minimum inhibitory concentration (MIC) of the pathogen.</p><p>&nbsp;</p><p><em>Susceptibility</em></p><p>The prevalence of resistance may vary geographically and over time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some of types of infections is questionable.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Commonly susceptible species</em></strong></p><p><strong>Aerobic Gram-positive bacteria</strong></p><p><em>Corynebacterium jeikeium&nbsp;<sup>a</sup></em></p><p><em>Enterococcus faecalis</em></p><p><em>Staphylococcus aureus&nbsp;</em>(including methicillin-resistant strains)</p><p><em>Streptococcus agalactiae</em></p><p><em>Streptococcus dysgalactiae&nbsp;</em>subsp.<em>&nbsp;equisimilis&nbsp;<sup>a</sup></em></p><p>(Group C &amp; G streptococci)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><em>Streptococcus pneumoniae</em></p><p><em>Streptococcus pyogenes</em></p><p>Streptococci in the viridans group&nbsp;<em><sup>a b</sup></em></p><p><strong>Anaerobic Gram-positive bacteria</strong></p><p><em>Clostridium difficile</em>&nbsp;<em><sup>a</sup></em></p><p><em>Peptostreptococcus spp.<sup>a</sup></em></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Species for which acquired resistance may be a problem</em></strong></p><p><strong>Aerobic Gram-positive bacteria</strong></p><p><em>Enterococcus faecium</em></p><p><em>Staphylococcus epidermidis</em></p><p><em>Staphylococcus haemolyticus</em></p><p><em>Staphylococcus hominis</em></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Inherently resistant bacteria</em></strong></p><p>All Gram-negative bacteria</p><p><strong>Other bacteria</strong></p><p><em>Chlamydia spp.</em></p><p><em>Chlamydophila spp.</em></p><p><em>Legionella pneumophila</em></p><p><em>Mycoplasma spp.</em></p></td></tr><tr><td style="vertical-align:top"><p><em>a)&nbsp;</em>No current data were available when the tables were published. The primary literature, standard volumes and treatment recommendations assume sensitivity</p><p><em>b)&nbsp;</em>Collective term for a heterogeneous group of streptococcus species. Resistance rate can vary depending on the actual streptococcus species</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>Teicoplanin is administered by parenteral route (intravenously or intramuscularly). After intramuscular administration, the bioavailability of teicoplanin (as compared to intravenous administration) is almost complete (90%). After six daily intramuscular administrations of 200 mg the mean (SD) maximum teicoplanin concentration (C<sub>max</sub>) amounts to 12.1 (0.9) mg/L and occurs at 2 hours after administration.</p><p>&nbsp;</p><p>After a loading dose of 6 mg/kg administered intravenously every 12 hours for 3 to 5 administrations, C<sub>max&nbsp;</sub>values range from 60 to 70 mg/L and C<sub>trough&nbsp;</sub>are usually above 10 mg/L. After an intravenous loading dose of 12 mg/kg administered every 12 hours for 3 administrations, mean values of C<sub>max&nbsp;</sub>and C<sub>trough&nbsp;</sub>are estimated to be around 100 mg/L and 20 mg/L, respectively.</p><p>&nbsp;</p><p>After a maintenance dose of 6 mg/kg administered once daily C<sub>max&nbsp;</sub>and C<sub>trough&nbsp;</sub>values are approximately 70 mg/L and 15 mg/L, respectively. After a maintenance dose of 12 mg/kg once daily C<sub>trough&nbsp;</sub>values range from 18 to 30 mg/L.</p><p>&nbsp;</p><p>When administered by oral route teicoplanin is not absorbed from the gastrointestinal tract.</p><p>&nbsp;</p><p>When administered by oral route at 250 or 500 mg single dose to healthy subjects, teicoplanin is not detected in serum or urine but only recovered in feces (about 45% of the administered dose) as unchanged medicinal product.</p><p>&nbsp;</p><p><strong>Distribution</strong></p><p>The binding to human serum proteins ranges from 87.6 to 90.8% without any variation in function of the teicoplanin concentrations. Teicoplanin is mainly bound to human serum albumin. Teicoplanin is not distributed in red cells.</p><p>&nbsp;</p><p>The volume of distribution at steady-state (Vss) varies from 0.7 to 1.4 L/kg. The highest values of Vss are observed in the recent studies where the sampling period was superior to 8 days.</p><p>&nbsp;</p><p>Teicoplanin distributed mainly in lung, myocardium and bone tissues with tissue/serum ratios superior to 1. In blister fluids, synovial fluid and peritoneal fluid the tissue/serum ratios ranged from 0.5 to 1. Elimination of teicoplanin from peritoneal fluid occurs at the same rate as from serum. In pleural fluid and subcutaneous fat tissue the tissue/serum ratios are comprised between 0.2 and 0.5. Teicoplanin does not readily penetrate into the cerebrospinal fluid (CSF).</p><p>&nbsp;</p><p><strong>Biotransformation</strong></p><p>Unchanged form of teicoplanin is the main compound identified in plasma and urine, indicating minimal metabolism. Two metabolites are formed probably by hydroxylation and represents 2 to 3% of the administered dose.</p><p>&nbsp;</p><p><strong>Elimination</strong></p><p>Unchanged teicoplanin is mainly excreted by urinary route (80% within 16 days) while 2.7% of the administered dose is recovered in feces (via bile excretion) within 8 days following administration.</p><p>&nbsp;</p><p>Elimination half-life of teicoplanin varies from 100 to 170 hours in the most recent studies where blood sampling duration is about 8 to 35 days.</p><p>&nbsp;</p><p>Teicoplanin has a low total clearance in the range of 10 to 14 ml/h/kg and a renal clearance in the range of 8 to 12 ml/h/kg indicating that teicoplanin is mainly excreted by renal mechanisms.</p><p>&nbsp;</p><p><strong>Linearity</strong></p><p>Teicoplanin exhibited linear pharmacokinetics at dose range of 2 to 25 mg/kg.</p><p>&nbsp;</p><p><strong>Special populations</strong></p><p><u>Renal impairment:</u></p><p>As teicoplanin is eliminated by renal route, teicoplanin elimination decreases according to the degree of renal impairment. The total and renal clearances of teicoplanin depends on the creatinine clearance.</p><p>&nbsp;</p><p><u>Elderly patients:</u></p><p>In the elderly population the teicoplanin pharmacokinetics is not modified unless in case of renal impairment.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>A higher total clearance (15.8 ml/h/kg for neonates, 14.8 ml/h/kg for a mean age 8 years) and a shorter elimination half-life (40 hours neonates; 58 hours for 8 years) are observed compared to adult patients.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following repeated parenteral administration to the rat and dog, effects on the kidney were observed and were shown to be dose-dependent and reversible. Studies to investigate the potential to cause ototoxicity in the guinea-pig indicate that a mild impairment of cochlear and vestibular function is possible, in the absence of morphological damage.</p><p>&nbsp;</p><p>Subcutaneous administration of teicoplanin at up to 40 mg/kg/day did not affect male and female fertility in the rat. In embryofetal development studies, no malformations were observed following subcutaneous administration of up to 200 mg/kg/day in the rat and intramuscular administration up to 15 mg/kg/day in the rabbit. However, in the rat, there was an increased incidence of stillbirths at doses of 100 mg/kg/day and above and neonatal mortality at 200 mg/kg/day. This effect was not reported at 50 mg/kg/day. A peri and postnatal study in rats showed no effects on the fertility of the F1 generation or on the survival and development of the F2 generation following subcutaneous administration of up to 40 mg/kg/day.</p><p>&nbsp;</p><p>Teicoplanin did not show any potential to cause antigenicity (in mice, guinea-pigs or rabbits), genotoxicity or local irritancy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium chloride</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Teicoplanin and aminoglycoside are incompatible when mixed directly and must not be mixed before injection.</p><p>&nbsp;</p><p>If teicoplanin is administered in combination therapy with other antibiotics, the preparation must be administered separately.</p><p>&nbsp;</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial: 
36 months.

Shelf life of reconstituted solution:
Chemical and physical in-use stability of the reconstituted solution prepared as recommended has been demonstrated for 24 hours at 2 to 8°C.

From a microbiological point of view, the medicinal product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution has taken place in controlled and validated aseptic conditions.

Shelf life of diluted medicinal product:
Chemical and physical in-use stability of the diluted solution prepared as recommended has been demonstrated for 24 hours at 2 to 8°C.

From a microbiological point of view, the medicinal product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package.</p><p>&nbsp;</p><p>Chemical and physical in-use stability of the reconstituted and diluted solution prepared as recommended has been demonstrated for 24 hours at 2 to 8&deg;C.</p><p>&nbsp;</p><p>For storage conditions of the reconstituted/diluted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 ml clear glass vials with grey rubber stoppers and aluminum caps.</p><p>&nbsp;</p><p>Pack size: 1 Vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product is for single use only.</p><p>&nbsp;</p><p><u>Preparation of reconstituted solution:</u></p><p>The solution is reconstituted by adding 3.14 ml of sterile water for injection to the 200 mg powder vial. The water is slowly added to the vial which should be rotated until all the powder is dissolved to avoid foaming. If foam is developed, allow the solution to stand for approximately 15 minutes so that the foam disappears. Only clear solutions should be used.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Nominal teicoplanin content of vial</p></td><td style="vertical-align:top"><p>200 mg</p></td></tr><tr><td style="vertical-align:top"><p>Volume of powder vial</p></td><td><p>10 ml</p></td></tr><tr><td style="vertical-align:top"><p>Volume containing nominal teicoplanin dose (extracted by 5 ml syringe and 23G needle)</p></td><td><p>3 ml</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Preparation of the diluted solution before infusion:</u></p><p>Targoplanin can be administered in the following infusion solutions:</p><ul><li>0.9% Sodium chloride solution</li><li>Ringer solution</li><li>Ringer-lactate solution</li><li>5% dextrose injection</li><li>10% dextrose injection</li><li>0.18% sodium chloride and 4% dextrose solution</li><li>0.45% sodium chloride and 5% dextrose solution</li><li>Peritoneal dialysis solution containing 1.36% dextrose.</li></ul><p>&nbsp;</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                26 May 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>